Drug Type Antibody fusion proteins |
Synonyms- |
Mechanism BTN2A1 inhibitors(Butyrophilin subfamily 2 member A1 inhibitors), BTN3A1 inhibitors(butyrophilin subfamily 3 member A1 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 08 Nov 2022 |